Optional extra-credit units

Role: transplant board member.

My stance: When donor livers are scarce, I rank patients first by medical urgency measured by the MELD score, because the sickest patient without a transplant has the least time left.

• Evidence I used: In our briefing, a patient with a MELD score of 35 had an estimated 3-month mortality near 80 percent, while a patient at MELD 15 was closer to 6 percent, so urgency is where a scarce organ saves the most life.
• Rebuttal I answered: The surgeon in our group ranked match quality first to lower rejection risk. My reply: a strong HLA match does not help a patient who dies on the waiting list before the next organ arrives, so urgency has to come before match quality when the supply is this tight.
• Class consensus ranking: 1) urgency, 2) match quality, 3) wait time.

(Tip: state your factor in one clean sentence, then attach exactly one number or piece of evidence to it so your stance is not just an opinion.)

Labeled recombinant-DNA flow (insulin example):

• Step 1, Isolate the gene: Cut the human insulin gene out of human DNA using a restriction enzyme such as EcoRI, which leaves sticky ends.
• Step 2, Cut the plasmid: Use the SAME restriction enzyme to open the bacterial plasmid, so its sticky ends match the gene's sticky ends.
• Step 3, Insert the gene: DNA ligase seals the human insulin gene into the plasmid. The result is recombinant DNA, meaning DNA combined from two sources.
• Step 4, Transform the host: Take up the recombinant plasmid into a host cell such as E. coli. The transformed bacterium now carries the human gene.
• Step 5, Manufacture the protein: The bacterium reads the inserted gene using the same genetic code all cells share, transcribes it to mRNA, and translates it into human insulin protein. Grow the culture and the bacteria make insulin in bulk.

Named product: human insulin (used to treat diabetes).

Why a bacterium can read a human gene: the genetic code is nearly universal, so the codons in the human gene mean the same amino acids inside the bacterial cell.

(Tip: label the restriction enzyme as the same tool in Step 1 and Step 2, since matching sticky ends is the part graders look for.)

Three-station data table (my recorded results):

• Purification station (chromatography column): Collected 6 fractions. Protein assay was strongest in Fraction 4 (dark blue, high signal) and Fraction 5 (medium), with Fractions 1-3 and 6 near zero. Conclusion: the target protein eluted in Fractions 4 and 5.
• HLA-matching station: Compared donor and recipient cards across 6 HLA loci. Matches at 5 of 6 loci; one mismatch at HLA-DR. Crossmatch score recorded as 5/6, flagged as a strong but not perfect match.
• Tissue station (scaffold comparison): Scaffold A (dense mesh) showed cell coverage about 45 percent after the modeled growth period; Scaffold B (porous mesh) showed about 78 percent. Note: the porous Scaffold B supported more cell growth, likely because pores let nutrients and cells move deeper.

One-line reading of each: high-protein fractions = 4 and 5; crossmatch = 5/6 (usable); better scaffold = B.

(Tip: write the actual number in every cell, even an estimate like 78 percent, because a data table with words but no values loses the most points.)

Comparison table for replacing a failing organ function:

• Engineered (scaffold + patient's own stem cells): Advantage: grown from the patient's own cells, so rejection risk is very low. Limitation: still experimental for whole organs and takes weeks to grow.
• Mechanical (device such as a mechanical heart valve or pump): Advantage: available now and works immediately. Limitation: needs power or blood-thinning drugs and can wear out or clot.
• Donor (transplanted human organ): Advantage: a real, fully functioning organ. Limitation: scarce supply and lifelong immunosuppression drugs to prevent rejection.

Sample patient: a 16-year-old needing a heart valve who wants to avoid lifelong blood thinners.

My recommendation: an engineered valve grown from her own cells, because it lowers rejection and clotting risk over a long life ahead, and time to grow it is acceptable since her condition is stable.

(Tip: make your patient pick match a real limitation you listed, so the justification points straight back to your own table.)

Unit 4 tracker checkpoint:

• Recombinant-DNA flow diagram: ATTACHED. Complete, all five steps labeled with the restriction enzyme named twice.
• Three-station data table: ATTACHED. All three rows have numbers (fractions 4 and 5, crossmatch 5/6, scaffold B 78 percent).
• Tissue-engineering comparison table: ATTACHED. Three columns filled, patient recommendation justified.
• Organ-allocation exit ticket: WEAK. My rebuttal sentence is missing. Fix plan: add one sentence answering the surgeon's match-quality argument before Friday.
• WebXam testing status: Confirmed CURRENT in the course shell; practice attempt logged, seat assigned.

Packet summary: 3 of 4 artifacts strong, 1 flagged with a same-week fix. Portfolio on track for the deadline.

(Tip: mark each item present, weak, or missing in one word, then write the fix as a dated action, so your checkpoint reads as a plan and not just a list.)

Role: allocation board member.

Claim: When supply is far below demand, I rank HLA match quality highest so the transplanted kidney lasts the longest.

Reason: A 5 of 6 HLA match in our class briefing had a projected graft survival near 12 years, while a 2 of 6 match projected closer to 6 years, so a better match returns more life-years per scarce kidney.

Rebuttal to the patient advocate (who ranks wait time first): Wait time feels fairer, but ignoring match quality means more early rejections and faster returns to the waiting list, which shrinks the total supply for everyone.

(Tip: state the other role's strongest version in one honest sentence before you answer it.)

Labeled nephron parts: glomerulus, Bowman's capsule, proximal tubule, loop of Henle, distal tubule, collecting duct.

Filtration in my words: Blood pressure pushes water and small solutes out of the glomerulus into Bowman's capsule as filtrate. As the filtrate moves down the tubule, the body reabsorbs what it needs (glucose, most water, sodium) back into the blood, and wastes like urea stay behind to leave as urine.

Sample lab values I read:

• Serum creatinine: 4.8 mg/dL (normal about 0.6 to 1.2)
• BUN: 62 mg/dL (normal about 7 to 20)
• eGFR: 14 mL/min/1.73m2 (normal above 90)

One-line interpretation: The high creatinine and BUN with an eGFR of 14 show the nephrons are barely filtering, so waste is building up in the blood and this signals kidney failure.

(Tip: creatinine and BUN go UP when filtration fails because the nephron can no longer clear them, so rising numbers mean worse filtering.)

Dialysis waste-level time series (recipient R):

• Start (0 min): urea 110 mg/dL
• 60 min: urea 78 mg/dL
• 120 min: urea 51 mg/dL
• 180 min: urea 33 mg/dL
• 240 min: urea 22 mg/dL

Reading: Dialysis pulled urea down from 110 to 22 mg/dL over four hours, modeling how the machine does the filtering the failed nephrons cannot.

HLA crossmatch scores (recipient R vs three donors):

• Donor A: 5 of 6 antigens match, no reaction in the well = COMPATIBLE
• Donor B: 3 of 6 match, weak reaction = BORDERLINE
• Donor C: 1 of 6 match, strong reaction = INCOMPATIBLE

Rejection-risk flags:

• Donor C flagged: a strong crossmatch reaction means the recipient already has antibodies against the donor tissue, so the immune system would attack the kidney quickly.

(Tip: a positive or strong crossmatch reaction is a stop sign, not a detail; it predicts fast rejection even if a few antigens match.)

Recipient: patient M. Donors ranked best to worst by HLA match:

• Donor 2: 6 of 6 match, crossmatch negative = rank 1 (best)
• Donor 1: 4 of 6 match, crossmatch negative = rank 2
• Donor 3: 2 of 6 match, crossmatch weak positive = rank 3 (worst)

Why a poor match is attacked (my words): Immune cells read the HLA markers on the donor kidney. When too many markers look foreign, T cells and antibodies treat the organ like an invader and attack its blood vessels and cells, which is rejection.

Immunosuppression:

• Benefit: The drugs calm the immune attack so even a good-but-not-perfect match can survive and keep filtering.
• Risk: A dialed-down immune system fights infections and some cancers less well, so the patient is more vulnerable to getting sick.

(Tip: a higher match number plus a negative crossmatch is what you want; ranking is not just the match count, the crossmatch can overrule it.)

Claim: The available kidney should go to Patient B rather than Patient A.

Evidence:

• Crossmatch: Patient B is a 5 of 6 HLA match with a negative crossmatch, while Patient A is a 2 of 6 match with a weak positive crossmatch.
• Urgency: Patient B's eGFR has fallen to 9 mL/min/1.73m2 and dialysis is no longer holding waste levels down, while Patient A is stable on dialysis with an eGFR of 15.

Reasoning: Patient B wins on both the biological and the urgency measures. The strong match with a negative crossmatch predicts long graft survival and low early rejection risk, so the scarce kidney is likely to last. Patient B is also more medically urgent because dialysis is failing to control their waste. Patient A's case is real, but a poor match with a positive crossmatch would risk fast rejection, which could waste the organ and send Patient A back to the list. Giving the kidney to the better match who is also more urgent returns the most life-years from a scarce resource.

(Tip: in a strong CER the reasoning does two jobs, it links your evidence to your claim AND says out loud why the other patient's evidence is weaker.)

Role: regulator.

My stance: Pig-organ transplants should move forward, but only under a licensed trial with a review board approving each patient.

Evidence: A gene-edited pig kidney kept a brain-dead recipient's blood filtered for over 50 days in a monitored study, which shows the organ can do real work before we scale up.

Strongest opposing argument (bioengineer): "Waiting for board approval on every case lets patients die who would take the risk today." My rebuttal: A review board is not a delay for its own sake; it catches the rejection and infection risks that would end the whole program if one uncontrolled failure made headlines.

(Tip: state the other side's strongest point in one fair sentence before you answer it, not a weak version you can knock down.)

Diagram labels, top to bottom:

• Scaffold: a porous, biodegradable mesh shaped like the tissue we want (here, a tube for a windpipe segment).
• Stem-cell seeding: undifferentiated stem cells are pipetted onto the scaffold and settle into its pores.
• Signals and nutrients: growth factors and a bioreactor bath tell the cells to divide and specialize.
• Differentiation: stem cells turn into the specific cell types the tissue needs, such as cartilage and lining cells.
• Organized tissue: cells fill the scaffold's shape while the scaffold slowly dissolves, leaving living tissue in the intended form.

Why shape matters: the scaffold is a physical template. Its tube shape guides cells to grow into a tube, so the finished tissue matches the airway it must replace.

Real application: lab-grown tracheal (windpipe) segments seeded on a scaffold.

(Tip: label the scaffold as a temporary shape guide that dissolves, not a permanent part of the finished organ.)

Compare three ways to replace lost function.

• Xenotransplantation (animal organ): Advantage: a living organ can do full biological work, such as filtering blood. Limitation: the human immune system attacks non-human tissue hard, so strong anti-rejection drugs are required. Failure mode: rejection, the immune system destroys the transplanted organ.
• Bionic device (for example, a cochlear implant or bionic eye): Advantage: does not trigger immune rejection because it is not living tissue. Limitation: needs power, electronics can fail, and it interfaces imperfectly with nerves. Failure mode: rejection-like failure is scar tissue or infection forming around the implant and blocking the signal.
• Prosthetic (external limb): Advantage: no surgery inside the body and easy to repair or replace. Limitation: replaces movement but not sensation or living function. Failure mode: rejection-like failure is skin breakdown and pressure sores where the socket meets the body.

Patient note: For a patient who needs kidney function, only the xenotransplant restores the biological job; a bionic or prosthetic cannot filter blood.

(Tip: for the non-living options, describe the 'rejection-like' failure as the body walling off or breaking down at the device, not true immune rejection.)

Case: a bionic hand for a patient who lost a hand below the wrist.

Function it must restore: grip and basic object handling so the patient can hold a cup and a phone.

Criteria evaluation: The design must (1) close and open on the patient's intent, (2) grip firmly enough to hold a full cup, and (3) be light enough to wear all day. It meets criteria 1 and 3: it reads muscle signals from the forearm and weighs about 400 grams. It partly meets criterion 2: it grips a cup but slips on smooth glass.

Strength: it responds to the patient's own muscle signals, so control feels natural and needs little training (case data: 90 percent of intended grips succeeded).

Weakness: it gives no sense of touch, so the patient must watch the hand to judge grip force, which slows tasks and causes drops on slick objects.

Proposed improvement: add pressure sensors in the fingertips that buzz the forearm when grip is firm.

Trade-off: the sensors and feedback motor add weight and drain the battery faster, so all-day wear (criterion 3) gets harder.

(Tip: tie every strength and weakness to a specific criterion, not to a general 'it works well' claim.)

Claim: Gene-edited pig kidneys are promising but not yet ready for routine patient use.

Evidence 1 (effectiveness): In a monitored study, a gene-edited pig kidney filtered a recipient's blood and produced urine for over 50 days, showing the organ can do real kidney work in a human body.

Evidence 2 (safety): The same trials still rely on heavy immune-suppression, and researchers watch closely for pig viruses (PERVs) that could pass to the patient, which is an unresolved safety risk.

Reasoning: The effectiveness evidence clears the first bar, the organ functions. But 'ready for patients' also means safe at scale, and the rejection and cross-species infection risks are not yet controlled well enough for routine surgery. So the honest verdict is promising, not ready.

Main barrier still to solve: controlling long-term rejection and the risk of animal viruses without immune-suppression so heavy that it endangers the patient.

(Tip: pick 'ready,' 'promising,' or 'not viable' on purpose and make your evidence match the verdict; do not claim 'ready' while your own evidence lists an unsolved risk.)

Dilemma: Should a recombinant-protein therapy be offered to a patient before the long-term rejection risk of an engineered tissue graft is fully known?

Role: transplant ethicist.

Claim: Yes, offer the recombinant-protein therapy first, because it treats the failing function with a lower biological risk than an engineered graft.

Evidence 1 (recombinant DNA unit): a host cell reliably manufactures a known human protein such as insulin, so dosing and purity are controllable.

Evidence 2 (tissue-engineering unit): a scaffold-plus-stem-cell graft can still trigger rejection-like failure, which adds an unpredictable risk the protein therapy avoids.

Rebuttal to the bioengineer role: they argue the graft is a permanent fix while the protein must be re-dosed, but a repeatable low-risk treatment beats a one-time treatment that may fail immunologically.

(Tip: pulling one piece of evidence from a molecular unit and one from a whole-organ unit is what makes this a cross-unit answer instead of a single-topic answer.)

Patient core problem: kidneys are failing, so waste is building up in the blood.

Map from molecule to patient:

• Diagnosis: renal lab values (high blood waste) plus HLA typing flag the failure and set up matching.
• Intervention 1, dialysis: filters waste from the blood to keep the patient stable while they wait.
• Intervention 2, HLA crossmatching: scores donor-recipient compatibility so a poorly matched organ is not transplanted.
• Intervention 3, immunosuppression: lowers the immune attack after transplant so a matched kidney is not rejected.

Outcome: the patient moves from unstable failure to a matched, medication-supported transplant.

How each moves the patient forward: dialysis buys time, crossmatching lowers rejection risk, immunosuppression protects the graft.

(Tip: label the exact tool at each arrow, not just the disease, so a reader can see the molecule-to-patient chain.)

Artifact checklist:

• Recombinant-DNA flow diagram: present, labeled.
• Three-station data table: present, but missing the scaffold-comparison row (weak).
• Tissue-engineering comparison table: present, labeled.
• Allocation CER: missing.
• Final-ethics exit ticket: present, labeled.

Gap log, ranked by time to close:

1. Add scaffold-comparison row to the station table, about 15 minutes.

2. Write the allocation CER (claim, two evidence points, reasoning), about 45 minutes.

Confidence this audit caught every gap: 85 percent. I am least sure the station table is complete because I reused an older file and may have an unlabeled column.

(Tip: rank gaps by minutes-to-close, not by how important they feel, so you fix the fast ones first and do not run out of time.)

Starting gap log (top priority first):

1. Allocation CER: missing.

2. Scaffold-comparison row on station table: incomplete.

Work done today:

• Allocation CER: closed. Wrote a claim naming the recipient, cited crossmatch score and urgency as evidence, and reasoned why competing evidence was outweighed.
• Scaffold-comparison row: closed. Added the row with cell-growth notes and units.

Remaining open items: none in the top two; one low-priority formatting cleanup on the diagram caption still open.

WebXam testing status: confirmed current in the course shell.

Confidence the top gaps are truly closed to standard: 90 percent. The one point of doubt is whether my CER reasoning is specific enough about why urgency outweighed a slightly better match.

(Tip: close items top-down from the ranked log so the artifacts that block a complete portfolio get finished first.)

Final check against the checklist:

• Recombinant-DNA flow diagram: attached, labeled.
• Three-station data table (all rows complete): attached, labeled.
• Tissue-engineering comparison table: attached, labeled.
• Allocation CER: attached, labeled.
• Final-ethics exit ticket and integrated-case map: attached, labeled.

Gap log: zero open items.

WebXam testing status: confirmed current.

Closing reflection: my strongest piece of evidence is the allocation CER, because it ties crossmatch data and urgency into one recommendation and shows I can reason across matching and ethics, not just recall terms.

Confidence the portfolio is complete and submission-ready: 95 percent. The remaining 5 percent is a formatting worry that one file name may not match the checklist label exactly.

(Tip: verify the gap log reads zero open items before you hit submit; a leftover open item is the most common reason a portfolio comes back.)